TNSN01019A1 - Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant - Google Patents
Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenantInfo
- Publication number
- TNSN01019A1 TNSN01019A1 TNTNSN01019A TNSN01019A TNSN01019A1 TN SN01019 A1 TNSN01019 A1 TN SN01019A1 TN TNSN01019 A TNTNSN01019 A TN TNSN01019A TN SN01019 A TNSN01019 A TN SN01019A TN SN01019 A1 TNSN01019 A1 TN SN01019A1
- Authority
- TN
- Tunisia
- Prior art keywords
- compositions containing
- isoezymes
- pde4
- inhibitors
- pyrimidinecarboxamides
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
- C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
- C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
- C07D239/32—One oxygen, sulfur or nitrogen atom
- C07D239/34—One oxygen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00ย -ย A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/14—Decongestants or antiallergics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/12—Antidiuretics, e.g. drugs for diabetes insipidus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Hematology (AREA)
- Pulmonology (AREA)
- Physical Education & Sports Medicine (AREA)
- Heart & Thoracic Surgery (AREA)
- Oncology (AREA)
- Rheumatology (AREA)
- Communicable Diseases (AREA)
- Neurology (AREA)
- Immunology (AREA)
- Molecular Biology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Epidemiology (AREA)
- Biotechnology (AREA)
- Vascular Medicine (AREA)
- Dermatology (AREA)
- Ophthalmology & Optometry (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US17928200P | 2000-01-31 | 2000-01-31 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TNSN01019A1 true TNSN01019A1 (fr) | 2005-11-10 |
Family
ID=22655926
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNTNSN01019A TNSN01019A1 (fr) | 2000-01-31 | 2001-01-31 | Pyrimidinecarboxamides utiles comme inhibiteurs d'iso-ezymes pde4, et compositions les contenant |
Country Status (45)
Families Citing this family (86)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2165768B1 (es) | 1999-07-14 | 2003-04-01 | Almirall Prodesfarma Sa | Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen. |
| EP1248597B1 (en) * | 1999-12-24 | 2005-03-30 | Glaxo Group Limited | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| DE10110772A1 (de) * | 2001-03-07 | 2002-09-12 | Boehringer Ingelheim Pharma | Neue Arzneimittelkompositionen auf der Basis von Anticholinergika und PDE-IV-Inhibitoren |
| US7776315B2 (en) | 2000-10-31 | 2010-08-17 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmaceutical compositions based on anticholinergics and additional active ingredients |
| YU39503A (sh) * | 2000-11-22 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati pirimidina |
| JP2004520386A (ja) * | 2001-01-31 | 2004-07-08 | ใใกใคใถใผใปใใญใใฏใใปใคใณใฏ | ๏ผฐ๏ฝ๏ฝ ๏ผใขใคใฝใถใคใ ใฎ้ปๅฎณๅคใจใใฆๆ็จใชใใณใใณใขใใใใขใชใผใซ่ชๅฐไฝ |
| OA12542A (en) | 2001-01-31 | 2006-06-05 | Pfizer Prod Inc | Thiazolyl-, oxazolyl-, pyrrolyl-, and imidazolyl-acid amide derivatives useful as inhibitors of PDE4isozymes. |
| US7250518B2 (en) | 2001-01-31 | 2007-07-31 | Pfizer Inc. | Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes |
| KR20030070150A (ko) * | 2001-01-31 | 2003-08-27 | ํ์ด์ ํ๋ก๋์ธ ์ธํฌ. | ๏ผฐ๏ฝ๏ฝ 4 ์ด์์์ ์ต์ ์ ๋ก์ ์ ์ฉํ ์ํ ๋ฅด ์ ๋์ฒด |
| ATE293109T1 (de) * | 2001-01-31 | 2005-04-15 | Pfizer Prod Inc | Nikotinsรคureamid-derivate und ihre mimetika als inhibitoren von pde4-isozyms |
| WO2002094320A1 (en) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Therapeutic compositions for repairing chondropathy |
| WO2002094321A1 (en) * | 2001-05-23 | 2002-11-28 | Tanabe Seiyaku Co., Ltd. | Compositions for promoting healing of bone fracture |
| DE10142176A1 (de) * | 2001-08-29 | 2003-03-27 | Eucro Europe Contract Res Gmbh | Verwendung einer Kombination aus ร-adrenergen Agonisten und NDMA-Antagonisten |
| DE10163991A1 (de) * | 2001-12-24 | 2003-07-03 | Merck Patent Gmbh | Pyrrolo-pyrimidine |
| MY140561A (en) | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
| US6951869B2 (en) * | 2002-02-26 | 2005-10-04 | Schlesinger Stephen L | Use of leukotriene receptor antagonist for treatment of scarring |
| TR201815573T4 (tr) * | 2002-05-28 | 2018-11-21 | Astrazeneca Ab | Topikal olarak uygulanabilir farmasรถtik preparasyon. |
| DE10224888A1 (de) | 2002-06-05 | 2003-12-24 | Merck Patent Gmbh | Pyridazinderivate |
| GB2389530B (en) | 2002-06-14 | 2007-01-10 | Cipla Ltd | Pharmaceutical compositions |
| US20040001895A1 (en) * | 2002-06-17 | 2004-01-01 | Pfizer Inc. | Combination treatment for depression and anxiety |
| RU2327450C2 (ru) * | 2002-08-29 | 2008-06-27 | ะกะธะฟะปะฐ ะะธะผะธัะตะด | ะคะฐัะผะฐัะตะฒัะธัะตัะบะธะต ะฟัะพะดัะบัั ะธ ะบะพะผะฟะพะทะธัะธะธ, ัะพะดะตัะถะฐัะธะต ัะฟะตัะธัะธัะตัะบะธะต ะฐะฝัะธั ะพะปะธะฝะตัะณะธัะตัะบะธะต ััะตะดััะฒะฐ, ะฐะณะพะฝะธััั ะฑะตัะฐ-2 ะธ ะบะพััะธะบะพััะตัะพะธะดั |
| US9415102B2 (en) | 2002-09-06 | 2016-08-16 | Alexion Pharmaceuticals, Inc. | High concentration formulations of anti-C5 antibodies |
| ES2614274T3 (es) * | 2002-09-06 | 2017-05-30 | Alexion Pharmaceuticals, Inc. | Procedimiento de tratamiento de asma usando anticuerpos frente al componente de complemento C5 |
| US20050271660A1 (en) | 2002-09-06 | 2005-12-08 | Alexion Pharmaceuticals, Inc. | Nebulization of monoclonal antibodies for treating pulmonary diseases |
| US7851486B2 (en) | 2002-10-17 | 2010-12-14 | Decode Genetics Ehf. | Susceptibility gene for myocardial infarction, stroke, and PAOD; methods of treatment |
| US7507531B2 (en) | 2002-10-17 | 2009-03-24 | Decode Genetics Chf. | Use of 5-lipoxygenase activating protein (FLAP) gene to assess susceptibility for myocardial infarction |
| US20040225077A1 (en) | 2002-12-30 | 2004-11-11 | Angiotech International Ag | Drug delivery from rapid gelling polymer composition |
| AU2004232858B2 (en) | 2003-04-23 | 2009-07-09 | Mannkind Corporation | Hydraulically actuated pump for long duration medicament administration |
| US7439241B2 (en) * | 2003-05-27 | 2008-10-21 | Galderma Laboratories, Inc. | Compounds, formulations, and methods for treating or preventing rosacea |
| GB0317516D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317484D0 (en) | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US7153870B2 (en) | 2003-07-25 | 2006-12-26 | Pfizer Inc. | Nicotinamide derivatives useful as PDE4 inhibitors |
| US7132435B2 (en) | 2003-07-25 | 2006-11-07 | Pfizer Inc. | Compounds |
| GB0317498D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Compounds |
| US20050020587A1 (en) * | 2003-07-25 | 2005-01-27 | Pfizer Inc | Nicotinamide derivatives useful as PDE4 inhibitors |
| GB0317482D0 (en) * | 2003-07-25 | 2003-08-27 | Pfizer Ltd | Nicotinamide derivatives useful as pde4 inhibitors |
| US20050059643A1 (en) * | 2003-08-05 | 2005-03-17 | Boehringer Ingelheim International Gmbh | Medicaments for inhalation comprising a steroid and a betamimetic |
| CA2534352A1 (en) * | 2003-08-08 | 2005-02-17 | Arriva Pharmaceuticals, Inc. | Methods of protein production in yeast |
| US20050142104A1 (en) * | 2003-11-06 | 2005-06-30 | Zeldis Jerome B. | Methods of using and compositions comprising PDE4 modulators for the treatment and management of asbestos-related diseases and disorders |
| JP2007511539A (ja) * | 2003-11-14 | 2007-05-10 | ใใฏในใฟใผใปใคใณใฟใผใใทใงใใซใปใคใณใณใผใใฌใคใใใ | ฮฑ๏ผโๆใใชใใทใณ็ตๆ็ฉใใใณใใฎใใใช็ตๆ็ฉใ็จใใๅฆ็ฝฎๆนๆณ |
| US20090042951A1 (en) * | 2004-02-20 | 2009-02-12 | Robert Danziger | Blood Pressure Reduction in Salt-Sensitive Hypertension |
| JP2007528409A (ja) * | 2004-03-09 | 2007-10-11 | ใขใชใ ใใกใผใใทใฅใผใใฃใซใซใบ๏ผ ใคใณใณใผใใฌใคใใใ | ใใญใใขใผใผใคใณใใใฟใผใฎไฝ็จ้ๅธๅ ฅใซใใๆ ขๆง้ๅกๆง่บ็พๆฃใฎๅฆ็ฝฎ |
| JP2007533761A (ja) * | 2004-04-23 | 2007-11-22 | ใปใซใธใผใณใปใณใผใใฌใผใทใงใณ | ่บ้ซ่กๅง็ใๆฒป็ใ็ฎก็ใใใใใฎใๅ ็ซ่ชฟ็ฏๆงๅๅ็ฉใฎไฝฟ็จๆนๆณๅใณๅ ็ซ่ชฟ็ฏๆงๅๅ็ฉใๅซใ็ตๆ็ฉ |
| PE20060272A1 (es) | 2004-05-24 | 2006-05-22 | Glaxo Group Ltd | (2r,3r,4s,5r,2'r,3'r,4's,5's)-2,2'-{trans-1,4-ciclohexanodiilbis-[imino(2-{[2-(1-metil-1h-imidazol-4-il)etil]amino}-9h-purin-6,9-diil)]}bis[5-(2-etil-2h-tetrazol-5-il)tetrahidro-3,4-furanodiol] como agonista a2a |
| WO2006014425A1 (en) | 2004-07-02 | 2006-02-09 | Biovalve Technologies, Inc. | Methods and devices for delivering glp-1 and uses thereof |
| RU2279878C2 (ru) * | 2004-08-17 | 2006-07-20 | ะะพััะดะฐัััะฒะตะฝะฝะพะต ะพะฑัะฐะทะพะฒะฐัะตะปัะฝะพะต ัััะตะถะดะตะฝะธะต ะฒัััะตะณะพ ะฟัะพัะตััะธะพะฝะฐะปัะฝะพะณะพ ะพะฑัะฐะทะพะฒะฐะฝะธั "ะะะจะะะ ะกะะะ ะะะกะฃะะะ ะกะขะะะะะซะ ะะะะะฆะะะกะะะ ะฃะะะะะ ะกะะขะะข ะคะตะดะตัะฐะปัะฝะพะณะพ ะะณะตะฝัััะฒะฐ ะฟะพ ะทะดัะฐะฒะพะพั ัะฐะฝะตะฝะธั ะธ ัะพัะธะฐะปัะฝะพะผั ัะฐะทะฒะธัะธั" (ะะะฃ ะะะ ะะะะฃ ะ ะะกะะะ ะะะ) | ะกะฟะพัะพะฑ ะทะฐัะธัั ะณะพะปะพะฒะฝะพะณะพ ะผะพะทะณะฐ ะฒ ัะตะบะพะฝััััะบัะธะฒะฝะพะน ั ะธัััะณะธะธ ัะพะฝะฝัั ะฐััะตัะธะน |
| ES2901955T3 (es) | 2004-10-08 | 2022-03-24 | Abbvie Inc | Sal meglumรญnica y formas cristalinas de la misma de un farmaco (delafloxacina) |
| US20070105768A1 (en) * | 2004-11-10 | 2007-05-10 | Rajiv Nayar | Dry recombinant human alpha 1-antitrypsin formulation |
| US7820637B2 (en) * | 2005-03-17 | 2010-10-26 | Proyecto De Biomedicina Cima, S.L. | Use of 5โฒ-methylthioadenosine (MTA) in the prevention and/or treatment of autoimmune diseases and/or transplant rejection |
| GB0514809D0 (en) | 2005-07-19 | 2005-08-24 | Glaxo Group Ltd | Compounds |
| JP2009506069A (ja) | 2005-08-26 | 2009-02-12 | ใใฌใคใณใปใซใน๏ผใคใณใณใผใใฌใคใใฃใ | ใ ในใซใชใณๆงๅๅฎนไฝ่ชฟ็ฏใซใใ็ฅ็ต็บ็ |
| EP2258359A3 (en) | 2005-08-26 | 2011-04-06 | Braincells, Inc. | Neurogenesis by muscarinic receptor modulation with sabcomelin |
| US7985756B2 (en) | 2005-10-21 | 2011-07-26 | Braincells Inc. | Modulation of neurogenesis by PDE inhibition |
| WO2007053596A1 (en) | 2005-10-31 | 2007-05-10 | Braincells, Inc. | Gaba receptor mediated modulation of neurogenesis |
| ZA200804550B (en) | 2005-11-09 | 2009-08-26 | Combinatorx Inc | Methods, compositions, and kits for the treatment of medical conditions |
| US20100216734A1 (en) | 2006-03-08 | 2010-08-26 | Braincells, Inc. | Modulation of neurogenesis by nootropic agents |
| AU2007233231B2 (en) | 2006-03-30 | 2011-02-24 | Mannkind Corporation | Multi-cartridge fluid delivery device |
| WO2007134136A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | Neurogenesis by modulating angiotensin |
| WO2007134077A2 (en) | 2006-05-09 | 2007-11-22 | Braincells, Inc. | 5 ht receptor mediated neurogenesis |
| EP2068872A1 (en) | 2006-09-08 | 2009-06-17 | Braincells, Inc. | Combinations containing a 4-acylaminopyridine derivative |
| US20100184806A1 (en) | 2006-09-19 | 2010-07-22 | Braincells, Inc. | Modulation of neurogenesis by ppar agents |
| US8071596B2 (en) * | 2007-01-12 | 2011-12-06 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| US8080549B2 (en) * | 2007-01-12 | 2011-12-20 | Concert Pharmaceuticals, Inc. | Endothelin receptor antagonists |
| GB0706398D0 (en) * | 2007-04-02 | 2007-05-09 | Univ Hospital Of North Staford | Improvements in and relating to copd determination |
| RU2009141592A (ru) * | 2007-04-11 | 2011-05-20 | ะะปัะบะพะฝ ะ ะธัะตัั, ะัะด. (Us) | ะะ ะะะะะะะะ ะะะะะะะขะะ ะ TNFฮฑ ะ ะกะะงะะขะะะะ ะก ะะะขะะะะกะขะะะะะะซะ ะกะ ะะะกะขะะะ ะะะฏ ะะะงะะะะฏ ะะะะะ ะะะงะะกะะะะ ะ ะะะะขะ ะ ะะะะะ ะะะงะะกะะะะ ะะะะชะฎะะะขะะะะขะ |
| US7982036B2 (en) | 2007-10-19 | 2011-07-19 | Avila Therapeutics, Inc. | 4,6-disubstitued pyrimidines useful as kinase inhibitors |
| US7989465B2 (en) | 2007-10-19 | 2011-08-02 | Avila Therapeutics, Inc. | 4,6-disubstituted pyrimidines useful as kinase inhibitors |
| EP2100599A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| EP2100598A1 (en) | 2008-03-13 | 2009-09-16 | Laboratorios Almirall, S.A. | Inhalation composition containing aclidinium for treatment of asthma and chronic obstructive pulmonary disease |
| US8138339B2 (en) | 2008-04-16 | 2012-03-20 | Portola Pharmaceuticals, Inc. | Inhibitors of protein kinases |
| MX2010011463A (es) | 2008-04-16 | 2011-06-03 | Portola Pharm Inc | 2,6-diamino-pirimidin-5-il-carboxamidas como inhibidores de syk o jak quinasas. |
| AU2008359989A1 (en) * | 2008-07-30 | 2010-02-04 | Nitto Denko Corporation | Drug carriers |
| EP2196465A1 (en) | 2008-12-15 | 2010-06-16 | Almirall, S.A. | (3-oxo)pyridazin-4-ylurea derivatives as PDE4 inhibitors |
| WO2010099217A1 (en) | 2009-02-25 | 2010-09-02 | Braincells, Inc. | Modulation of neurogenesis using d-cycloserine combinations |
| EP2226323A1 (en) | 2009-02-27 | 2010-09-08 | Almirall, S.A. | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives |
| EP2380890A1 (en) | 2010-04-23 | 2011-10-26 | Almirall, S.A. | New 7,8-dihydro-1,6-naphthyridin-5(6h)-one-derivatives as PDE4 inhibitors |
| EP2394998A1 (en) | 2010-05-31 | 2011-12-14 | Almirall, S.A. | 3-(5-Amino-6-oxo-1,6-dihydropyridazin-3-yl)-biphenyl derivatives as PDE4 inhibitors |
| WO2012133492A1 (ja) * | 2011-03-31 | 2012-10-04 | ใใซใๆ ชๅผไผ็คพ | ่ฃฝๅคๅฎๅฎๆงใซๅชใใ่ป่ๅค |
| EP2510928A1 (en) | 2011-04-15 | 2012-10-17 | Almirall, S.A. | Aclidinium for use in improving the quality of sleep in respiratory patients |
| CN102850321A (zh) * | 2011-06-28 | 2013-01-02 | ไธญๅฝ็งๅญฆ้ขไธๆตท่ฏ็ฉ็ ็ฉถๆ | ่ณ้ฆๆฐงๅบๅงๅถ็ฒ้ ฐ่บๆ่ณ้ฆๆฐงๅบๅกๅถ็ฒ้ ฐ่บ็ฑปๅๅ็ฉๅๅ ถๅถๅคๆนๆณใ่ฏ็ฉ็ปๅ็ฉๅ็จ้ |
| SG11201402570QA (en) | 2011-11-23 | 2014-06-27 | Portola Pharm Inc | Pyrazine kinase inhibitors |
| EP2804603A1 (en) | 2012-01-10 | 2014-11-26 | President and Fellows of Harvard College | Beta-cell replication promoting compounds and methods of their use |
| KR102006547B1 (ko) * | 2017-11-16 | 2019-08-01 | ์์ธ๋ํ๊ต์ฐํํ๋ ฅ๋จ | ๋ฒค์ฆ์๋ฏธ๋ ์ ๋์ฒด ํํฉ๋ฌผ, ์ด์ ์ ์กฐ๋ฐฉ๋ฒ ๋ฐ ์ด๋ฅผ ์ ํจ์ฑ๋ถ์ผ๋ก ํจ์ ํ๋ ์ผ์ฆ์งํ์ ์น๋ฃ ๋๋ ์๋ฐฉ์ฉ ์ฝํ์ ์กฐ์ฑ๋ฌผ |
| AU2019207288A1 (en) * | 2018-01-11 | 2020-08-13 | Emphysema Solutions Bv | Compositions and methods for the treatment of lung emphysema and other forms of COPD |
| KR102200032B1 (ko) * | 2019-03-13 | 2021-01-08 | ์ ๋จ๋ํ๊ต์ฐํํ๋ ฅ๋จ | ํธํก๊ธฐ ์งํ์ ์๋ฐฉ ๋๋ ์น๋ฃ์ฉ ์กฐ์ฑ๋ฌผ |
| US11116737B1 (en) | 2020-04-10 | 2021-09-14 | University Of Georgia Research Foundation, Inc. | Methods of using probenecid for treatment of coronavirus infections |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4861891A (en) * | 1988-08-31 | 1989-08-29 | Pfizer Inc. | Antidepressant N-substituted nicotinamide compounds |
| TW429148B (en) * | 1995-10-27 | 2001-04-11 | Pfizer | Pharmaceutical agents for the treatment of acute and chronic inflammatory diseases |
| SK132899A3 (en) | 1997-04-04 | 2000-09-12 | Pfizer Prod Inc | NICOTINAMIDE DERIVATIVES AND PHARMACEUTICAL COMPOSITIONรฌ (54) COMPRISING THEM |
| YU39503A (sh) * | 2000-11-22 | 2006-05-25 | F. Hoffmann-La Roche Ag. | Derivati pirimidina |
-
2001
- 2001-01-30 AU AU27003/01A patent/AU2700301A/en not_active Abandoned
- 2001-01-30 EA EA200200739A patent/EA005028B1/ru not_active IP Right Cessation
- 2001-01-30 DK DK01901334T patent/DK1252157T3/da active
- 2001-01-30 PL PL01357555A patent/PL357555A1/xx not_active Application Discontinuation
- 2001-01-30 ES ES01901334T patent/ES2223772T3/es not_active Expired - Lifetime
- 2001-01-30 CA CA002396458A patent/CA2396458C/en not_active Expired - Fee Related
- 2001-01-30 EP EP01901334A patent/EP1252157B1/en not_active Expired - Lifetime
- 2001-01-30 KR KR1020027009810A patent/KR20020071029A/ko not_active Ceased
- 2001-01-30 CN CN01804403A patent/CN1404480A/zh active Pending
- 2001-01-30 DZ DZ013406A patent/DZ3406A1/fr active
- 2001-01-30 GE GE4896A patent/GEP20043385B/en unknown
- 2001-01-30 MX MXPA02007465A patent/MXPA02007465A/es active IP Right Grant
- 2001-01-30 BR BR0107934-4A patent/BR0107934A/pt not_active IP Right Cessation
- 2001-01-30 JP JP2001557857A patent/JP2003522165A/ja active Pending
- 2001-01-30 HU HU0204271A patent/HUP0204271A3/hu unknown
- 2001-01-30 US US10/181,417 patent/US6740655B2/en not_active Expired - Fee Related
- 2001-01-30 TR TR2004/02292T patent/TR200402292T4/xx unknown
- 2001-01-30 IL IL15048601A patent/IL150486A0/xx unknown
- 2001-01-30 WO PCT/IB2001/000125 patent/WO2001057025A1/en not_active Ceased
- 2001-01-30 AT AT01901334T patent/ATE269860T1/de not_active IP Right Cessation
- 2001-01-30 PT PT01901334T patent/PT1252157E/pt unknown
- 2001-01-30 AP APAP/P/2002/002590A patent/AP2002002590A0/en unknown
- 2001-01-30 EE EEP200200426A patent/EE200200426A/xx unknown
- 2001-01-30 DE DE60103976T patent/DE60103976T2/de not_active Expired - Fee Related
- 2001-01-30 NZ NZ519726A patent/NZ519726A/en unknown
- 2001-01-30 SK SK1034-2002A patent/SK10342002A3/sk unknown
- 2001-01-30 CZ CZ20022413A patent/CZ20022413A3/cs unknown
- 2001-01-30 HK HK03106472.1A patent/HK1054232A1/zh unknown
- 2001-01-30 OA OA1200200230A patent/OA12170A/en unknown
- 2001-01-31 TN TNTNSN01019A patent/TNSN01019A1/fr unknown
- 2001-01-31 PE PE2001000112A patent/PE20011059A1/es not_active Application Discontinuation
- 2001-01-31 GT GT200100023A patent/GT200100023A/es unknown
- 2001-01-31 UY UY26570A patent/UY26570A1/es not_active Application Discontinuation
- 2001-01-31 PY PY200100102108A patent/PY0102108A/es unknown
- 2001-01-31 AR ARP010100435A patent/AR027336A1/es not_active Application Discontinuation
- 2001-01-31 CO CO01007018A patent/CO5271669A1/es not_active Application Discontinuation
- 2001-01-31 SV SV2001000298A patent/SV2001000298A/es not_active Application Discontinuation
- 2001-01-31 PA PA20018511301A patent/PA8511301A1/es unknown
- 2001-06-30 HN HN2001000018A patent/HN2001000018A/es unknown
-
2002
- 2002-06-24 BG BG106868A patent/BG106868A/xx unknown
- 2002-06-25 IS IS6444A patent/IS6444A/is unknown
- 2002-07-24 CR CR6714A patent/CR6714A/es not_active Application Discontinuation
- 2002-07-29 MA MA26749A patent/MA26871A1/fr unknown
- 2002-07-29 ZA ZA200206034A patent/ZA200206034B/xx unknown
- 2002-07-30 NO NO20023614A patent/NO20023614L/no not_active Application Discontinuation
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TNSN02015A1 (fr) | Composes nouveaux antagonistes de ppar, et compositions les contenant | |
| TNSN01048A1 (fr) | Acides malonamiques et leurs derives, et compositions les contenant | |
| TNSN01020A1 (fr) | Derives heterocycliques benzocondenses de nicotinamide, et compositions les contenant | |
| TNSN02014A1 (fr) | Composes nouveaux agonistes de ppar et compositions les contenant | |
| TNSN01150A1 (fr) | Pyrimidine-2,4,6- triones inhibitrices de metalloproteinases, et compositions les contenant. | |
| TNSN98045A1 (fr) | Derives de nicotinamide nouveaux, procede pour leur preparation et compositions pharmaceutiques les contenant. | |
| TNSN02011A1 (fr) | Derives de pyrimidine bicycliques nouveaux, inhibiteurs de mmp, et compositions les contenant | |
| TNSN99155A1 (fr) | 1-aryl-3-arylmethyl-1,8-naphtyridine-4(1h)-ones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN01114A1 (fr) | Derives d'imidazole nouveaux et compositions les contenant | |
| TNSN02010A1 (fr) | Derives de pyrimidine nouveaux inhibiteurs de mmp, et compositions les contenant | |
| TNSN01149A1 (fr) | Spiro-pyrimidine-2,4,6-triones inhibitrices de metalloproteinases, et compositions les contenant. | |
| TNSN01132A1 (fr) | Derives de pyrazole nouveaux et compositions les contenant. | |
| TNSN99073A1 (fr) | Pyrazolopyrimidinones nouvelles, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN01124A1 (fr) | Derives de 1,4-dihydropyridine nouveaux , servant d'antagonistes de la bradykinine, et compositions les contenant | |
| TNSN99172A1 (fr) | 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN02032A1 (fr) | Derives de glutaramide a substituant n-phenpropylcyclopentyle nouveaux, et compositions les contenant. | |
| TNSN02022A1 (fr) | Triazolopyridines anti-inflammatoires nouvelles, et compositions les contenant | |
| TNSN01145A1 (fr) | Derives d'imidazole a noyau aryle ou heteroaryle condense, et compositions les contenant. | |
| TNSN02008A1 (fr) | Derives d'acides isophtalique nouveaux inhibiteurs de mmp, et compositions les contenant | |
| TNSN02021A1 (fr) | Derives de benzimidazole nouveaux, et compositions les contenant | |
| TNSN99171A1 (fr) | 4-carboxyamino-2-substitue-1,2,3,4-tetrahydroquinoleines, procede pour leur preparation et compositions pharmaceutiques les contenant | |
| TNSN02037A1 (fr) | Sulfonylpyridazinones nouvelles inhibitrices d'aldose reductase et compositions les contenant | |
| TNSN97198A1 (fr) | Derives de 6-phenylpyridyl-2- amine et compositions pharmaceutiques les contenant | |
| TNSN00191A1 (fr) | Composes nouveaux, compositions les contenant et leur utilisation dans le traitement d'une ischemie | |
| TNSN00121A1 (fr) | Composes nouveaux inhibiteurs de metalloproteases, procede pour leur preparation et compositions pharmaceutiques les contenant |